Advertisement

Journal of Neurology

, Volume 261, Issue 6, pp 1227–1233 | Cite as

Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy

  • Violaine Plante-BordeneuveEmail author
Neurological Update

Abstract

Transthyretin familial amyloid polyneuropathy (TTR-FAP) is a progressive neurodegenerative and systemic genetic disease first identified in Portugal, now reported worldwide. During the past few years our knowledge on the phenotypic presentation of this devastating condition has remarkably expanded including a wide variation in age of onset, different neuropathic patterns and patients presenting with isolated or predominant cardiac involvement. Liver transplantation, the first therapeutic approach, although invasive, has been shown to halt the progression of the neuropathy in young onset patients. Fortunately, several disease-modifying treatments are now available or in clinical development including TTR stabilizers and gene therapy. Their efficacy is higher if administered at the earliest disease stage. Thus, management of TTR-FAP patients is a moving field with need for early diagnosis using new diagnostic tools and new therapeutic options.

Keywords

Transthyretin Amyloidosis Polyneuropathy Genetics Therapeutics 

Notes

Acknowledgments

Investigator in the therapeutic trials on Tafamidis Fx 005 (2007–2009), Fx006 (2008–2010), Fx1A-201 (2008–2010), Fx1A-303 (2010–2012) sponsored by FoldRx pharmaceuticals inc. Acquired by Pfizer in 2011. Served as scientific advisor for the development of the data base “Transthyretin amyloidosis outcomes survey (THAOS)” (Pfizer inc.) and currently as member of the scientific board without financial support. Investigator in the international therapeutic trial ISIS 420915-CS2 sponsored by Isis pharmaceuticals (2013-ongoing).

References

  1. 1.
    Andrade C (1952) A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 75:408–427CrossRefPubMedGoogle Scholar
  2. 2.
    Plante-Bordeneuve V, Said G (2011) Familial amyloid polyneuropathy. Lancet Neurol 10(12):1086–1097CrossRefPubMedGoogle Scholar
  3. 3.
    Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, Obici L, Planté-Bordeneuve V, Rapezzi C, Said G, Salvi F (2013) Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 20(8–31):1–18Google Scholar
  4. 4.
    Benson MD, Kincaid JC (2007) The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 36:411–423CrossRefPubMedGoogle Scholar
  5. 5.
    Bulawa CE, Connelly S, Devit M et al (2012) Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 109(24):9629–9634PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Rapezzi C, Quarta CC, Obici L et al (2013) Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 34(7):520–528CrossRefPubMedGoogle Scholar
  7. 7.
    Said G (2003) Familial amyloid polyneuropathy: mechanisms leading to nerve degeneration. Amyloid 10(Suppl 1):7–12PubMedGoogle Scholar
  8. 8.
    Lefaucheur JP, Ng Wing Tin S, Kerschen P et al (2013) Neurophysiological markers of small fibre neuropathy in TTR-FAP mutation carriers. J Neurol 260:1497–1503CrossRefPubMedGoogle Scholar
  9. 9.
    Conceição I, Costa J, Castro J, de Carvalho M (2014) Neurophysiological techniques to detect early small-fiber dysfunction in transthyretin amyloid polyneuropathy. Muscle Nerve 49(2):181–186Google Scholar
  10. 10.
    Coutinho P, Martins da Silva A, Lopes Lima J, Resende Barbosa A (1980) Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In: Glenner GG, Pinho e Costa P, Falcao de Freitas A (eds) Amyloid and amyloidosis. Excerpta Medica, Amsterdam pp 88–98Google Scholar
  11. 11.
    Ikeda S, Nakazato M, Ando Y et al (2002) Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology 58:1001–1007CrossRefPubMedGoogle Scholar
  12. 12.
    Planté-Bordeneuve V, Ferreira A, Lalu T et al (2007) Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology 69:693–698CrossRefPubMedGoogle Scholar
  13. 13.
    Koike H, Morozumi S, Kawagashira Y et al (2009) The significance of carpal tunnel syndrome in transthyretin Val30Met familial amyloid polyneuropathy. Amyloid 16:142–148CrossRefPubMedGoogle Scholar
  14. 14.
    Ikeda S, Takei Y, Tokuda T, Nakazato M, Ando Y (2003) Clinical and pathological findings of non-Val30Met TTR type familial amyloid polyneuropathy in Japan. Amyloid 10(Suppl 1):39–47PubMedGoogle Scholar
  15. 15.
    Falk RH, Dubrey SW (2010) Amyloid heart disease. Prog Cardiovasc Dis 52:347–361CrossRefPubMedGoogle Scholar
  16. 16.
    Rapezzi C, Riva L, Quarta CC et al (2008) Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid 15(1):40–48CrossRefPubMedGoogle Scholar
  17. 17.
    Jacobson DR, Pastore RD, Yaghoubian R et al (1997) Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 336(7):466–473CrossRefPubMedGoogle Scholar
  18. 18.
    Hellman U, Alarcon F, Lundgren HE et al (2008) Heterogeneity of penetrance in hereditary transthyretin amyloid neuropathy in the Swedish population. Amyloid 15(3):181–186PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Lemos C, Coelho T, Alves-Ferreira M et al (2014) Overcoming artifact: anticipation in 284 Portuguese kindreds with familial amyloid polyneuropathy (FAP) ATTRV30M. J Neurol Neurosurg Psychiatry 85:326–330CrossRefPubMedGoogle Scholar
  20. 20.
    Benson M (2013) Liver transplantation and transthyretin amyloidosis. Muscle Nerve 47:157–162CrossRefPubMedGoogle Scholar
  21. 21.
    Wilczek HE, Larsson M, Ericzon BG (2011) Long term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR). Amyloid 18(Suppl. 1):188–190CrossRefGoogle Scholar
  22. 22.
    Yamashita T, Ando Y, Okamoto S, Misumi Y et al (2012) Long term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology 78:637–643CrossRefPubMedGoogle Scholar
  23. 23.
    Ihse E, Suhr OB, Hellman U, Westermark P (2011) Variation in amount of wildtype transthyretin in different fibril and tissue types in ATTR amyloidosis. J Mol Med (Berl) 89:171–180CrossRefGoogle Scholar
  24. 24.
    Conceição I, Evangelista T, Castro J et al (2010) Acquired amyloid polyneuropathy in a Portuguese patient after domino liver transplantation. Muscle Nerve 42:836–839CrossRefPubMedGoogle Scholar
  25. 25.
    Coelho T, Maia LF, da Silva AM et al (2013) Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 260:2802–2814PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Berk JL, Suhr OB, Obici L, Diflunisal Trial Consortium et al (2013) Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 310:2658–2667PubMedCentralCrossRefPubMedGoogle Scholar
  27. 27.
    Coelho T, Adams D, Silva A et al (2013) Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369:819–829CrossRefPubMedGoogle Scholar
  28. 28.
    Ackermann EJ, Guo S, Booten S et al (2012) Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 19(Suppl 1):43–44CrossRefPubMedGoogle Scholar
  29. 29.
    Cardoso I, Merlini G, Saraiva MJ et al (2003) 4′-iodo-4′-Deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibrils disrupters. FASEB J 17(8):803–809CrossRefPubMedGoogle Scholar
  30. 30.
    Obici L, Cortese A, Lozza A et al (2012) Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 19(Suppl 1):34–36CrossRefPubMedGoogle Scholar
  31. 31.
    Bodin K, Ellmerich S, Kahan MC et al (2010) Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 468(7320):93–97PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Planté-Bordeneuve V, Suhr OB, Maurer MS et al (2013) The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology. Curr Med Res Opin 29:77–84CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Amyloid Network, Department of NeurologyUniversity Hospital Henri Mondor, Assistance Publique - Hopitaux de Paris INSERM UMR955-Team 10, Paris East-Creteil UniversityCréteilFrance

Personalised recommendations